Nevertheless, a phase-1 trial (NCT02220842), including 14 patients with R/R FL and 17 patients with R/R DLBCL, showed the weak efficacy of atezolizumab in combination with obinutuzumab or the EZH2 inhibitor tazemetostat. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.